{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:25:56Z","timestamp":1792895156901,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009727","name":"Hospital Research Foundation","doi-asserted-by":"publisher","award":["2022-CF-EMCR-004-25314"],"award-info":[{"award-number":["2022-CF-EMCR-004-25314"]}],"id":[{"id":"10.13039\/100009727","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jconrel.2026.114711","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:22:36Z","timestamp":1770682956000},"page":"114711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery"],"prefix":"10.1016","volume":"392","author":[{"given":"Amin","family":"Ariaee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Noueihad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Wignall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah R.","family":"Wardill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive A.","family":"Prestidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.114711_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110605","article-title":"Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"198","author":"Li","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.jconrel.2026.114711_bb0010","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2026.114711_bb0015","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41366-023-01456-5","article-title":"Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study","volume":"48","author":"Ghusn","year":"2024","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.jconrel.2026.114711_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102539","article-title":"Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: a meta-analysis","volume":"16","author":"Dutta","year":"2022","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.jconrel.2026.114711_bb0025","article-title":"Real-world evidence of the effect of adjunctive semaglutide on weight change, glycemic control, and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes","author":"Mertens","year":"2025","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.jconrel.2026.114711_bb0030","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/dom.16065","article-title":"Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: post hoc analysis of three randomised controlled trials","volume":"27","author":"Armstrong","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jconrel.2026.114711_bb0035","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.114711_bb0040","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/jdi.14265","article-title":"Adherence and treatment discontinuation of oral semaglutide and once-weekly semaglutide injection at 12 month follow-up: Japanese real-world data","volume":"15","author":"Horii","year":"2024","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jconrel.2026.114711_bb0045","doi-asserted-by":"crossref","DOI":"10.2337\/db24-1873-LB","article-title":"1873-LB: comparison of adherence and persistence between oral Semaglutide and once-weekly Semaglutide injection at 12-month follow-up in Japanese real-world data","volume":"73","author":"Horii","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2026.114711_bb0050","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/pharmaceutics11020078","article-title":"Intestinal permeation enhancers for Oral delivery of macromolecules: a comparison between Salcaprozate sodium (SNAC) and sodium caprate (C10)","volume":"11","author":"Twarog","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114711_bb0055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejpb.2020.04.023","article-title":"A head-to-head Caco-2 assay comparison of the mechanisms of action of the intestinal permeation enhancers: SNAC and sodium caprate (C10)","volume":"152","author":"Twarog","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.114711_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105685","article-title":"Comparison of the effects of the intestinal permeation enhancers, SNAC and sodium caprate (C10): isolated rat intestinal mucosae and sacs","volume":"158","author":"Twarog","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.114711_bb0065","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1477-9560-4-6","article-title":"Oral heparin: status review","volume":"4","author":"Arbit","year":"2006","journal-title":"Thromb. J."},{"key":"10.1016\/j.jconrel.2026.114711_bb0070","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s40262-021-01025-x","article-title":"Clinical pharmacokinetics of Oral Semaglutide: analyses of data from clinical pharmacology trials","volume":"60","author":"Overgaard","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2026.114711_bb0075","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2020.05.007","article-title":"Systemic delivery of peptides by the oral route: formulation and medicinal chemistry approaches","volume":"157","author":"Brayden","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114711_bb0080","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/ajhp\/zxaa413","article-title":"Management of type 2 diabetes with oral semaglutide: practical guidance for pharmacists","volume":"78","author":"Kane","year":"2021","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.jconrel.2026.114711_bb0085","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40262-018-0728-4","article-title":"Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes","volume":"58","author":"Granhall","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2026.114711_bb0090","article-title":"Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system","volume":"15\u20132024","author":"Niu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.114711_bb0095","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2337\/cd22-0118","article-title":"Current understanding of sodium N-(8-[2-hydroxylbenzoyl] amino) caprylate (SNAC) as an absorption enhancer: the oral semaglutide experience","volume":"42","author":"Solis-Herrera","year":"2023","journal-title":"Clin. Diabetes"},{"key":"10.1016\/j.jconrel.2026.114711_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105509","article-title":"Salcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers","volume":"154","author":"Fattah","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.114711_bb0105","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12917-020-02451-y","article-title":"Updated guidelines for reporting animal research","volume":"16","author":"Du Sert","year":"2020","journal-title":"BMC Vet. Res."},{"key":"10.1016\/j.jconrel.2026.114711_bb0110","article-title":"The degree of inulin polymerization is important for short-term amelioration of high-fat diet (HFD)-induced metabolic dysfunction and gut microbiota dysbiosis in rats","volume":"13","author":"Ariaee","year":"2024","journal-title":"Foods"},{"key":"10.1016\/j.jconrel.2026.114711_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1282694","article-title":"Gut microbiota and metabolites in estrus cycle and their changes in a menopausal transition rat model with typical neuroendocrine aging","volume":"14","author":"Dai","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.jconrel.2026.114711_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2024.105789","article-title":"The impact of estrous cycle on anxiety-like behaviour during unlearned fear tests in female rats and mice: a systematic review and meta-analysis","volume":"164","author":"Pestana","year":"2024","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.jconrel.2026.114711_bb0125","article-title":"Effect of Estrous cycle on behavior of females in rodent tests of anxiety","volume":"12","author":"Lovick","year":"2021","journal-title":"Front. Psychol."},{"key":"10.1016\/j.jconrel.2026.114711_bb0130","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01517-24","article-title":"Temporary dietary fiber depletion prompts rapid and lasting gut microbiota restructuring in mice","volume":"13","author":"Rous","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.jconrel.2026.114711_bb0135","doi-asserted-by":"crossref","first-page":"19351","DOI":"10.1038\/s41598-022-21270-9","article-title":"Amoxicillin impact on pathophysiology induced by short term high salt diet in mice","volume":"12","author":"Kumar","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.114711_bb0140","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13099-022-00513-0","article-title":"Amoxicillin modulates gut microbiota to improve short-term high-fat diet induced pathophysiology in mice","volume":"14","author":"Kumar","year":"2022","journal-title":"Gut Pathog."},{"key":"10.1016\/j.jconrel.2026.114711_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2023.123688","article-title":"Novel LC-MS\/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats","volume":"1221","author":"Lee","year":"2023","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jconrel.2026.114711_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12020170","article-title":"A gas chromatography mass spectrometry-based method for the quantification of short chain fatty acids","volume":"12","author":"Rohde","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.jconrel.2026.114711_bb0155","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jconrel.2026.114711_bb0160","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.jconrel.2026.114711_bb0165","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jconrel.2026.114711_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/jcdd10040176","article-title":"Retrospective analysis of the effectiveness of oral semaglutide in type 2 diabetes mellitus and its effect on cardiometabolic parameters in Japanese clinical settings","volume":"10","author":"Yamada","year":"2023","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"10.1016\/j.jconrel.2026.114711_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12051001","article-title":"Effects of once-weekly semaglutide on cardiovascular risk factors and metabolic dysfunction-associated steatotic liver disease in Japanese patients with type 2 diabetes: a retrospective longitudinal study based on real-world data","volume":"12","author":"Katsuyama","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.jconrel.2026.114711_bb0180","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00592-022-01936-6","article-title":"Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes","volume":"59","author":"Di Folco","year":"2022","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.jconrel.2026.114711_bb0185","doi-asserted-by":"crossref","first-page":"15582","DOI":"10.1038\/s41598-019-52103-x","article-title":"Metabolic and gut microbiome changes following GLP-1 or dual GLP-1\/GLP-2 receptor agonist treatment in diet-induced obese mice","volume":"9","author":"Madsen","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.114711_bb0190","article-title":"Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake","author":"Klemets","year":"2024","journal-title":"medRxiv"},{"key":"10.1016\/j.jconrel.2026.114711_bb0195","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.clinthera.2011.05.088","article-title":"Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects","volume":"33","author":"Castelli","year":"2011","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jconrel.2026.114711_bb0200","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1080\/17425247.2023.2223937","article-title":"The impact of common pharmaceutical excipients on the gut microbiota","volume":"20","author":"Subramaniam","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.114711_bb0205","doi-asserted-by":"crossref","first-page":"eaar7047","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.114711_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.jconrel.2026.114711_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgae719","article-title":"Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and Tirzepatide","volume":"110","author":"Jalleh","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jconrel.2026.114711_bb0220","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/jdi.14005","article-title":"Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy","volume":"14","author":"Kobori","year":"2023","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jconrel.2026.114711_bb0225","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1136\/gutjnl-2017-315306","article-title":"Proton pump inhibitor use associated with changes in gut microbiota composition","volume":"67","author":"Reveles","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2026.114711_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms11051122","article-title":"Gastroparesis: the complex interplay with microbiota and the role of exogenous infections in the pathogenesis of the disease","volume":"11","author":"Mandarino","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.jconrel.2026.114711_bb0235","article-title":"Postoperative delayed gastric emptying: may gut microbiota play a role?","volume":"14","author":"Wang","year":"2024","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.jconrel.2026.114711_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/nu16162660","article-title":"Exploration of the muribaculaceae family in the gut microbiota: diversity, metabolism, and function","volume":"16","author":"Zhu","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.jconrel.2026.114711_bb0245","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/1758-2229.12980","article-title":"Polysaccharide degradation by the Bacteroidetes: mechanisms and nomenclature","volume":"13","author":"McKee","year":"2021","journal-title":"Environ. Microbiol. Rep."},{"key":"10.1016\/j.jconrel.2026.114711_bb0250","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1089\/chi.2019.0312","article-title":"Gut bacterial families are associated with body composition and metabolic risk markers in school-aged children in rural Mexico","volume":"16","author":"Aguilar","year":"2020","journal-title":"Child. Obes."},{"key":"10.1016\/j.jconrel.2026.114711_bb0255","doi-asserted-by":"crossref","first-page":"e0245219","DOI":"10.1371\/journal.pone.0245219","article-title":"Hepatic steatosis relates to gastrointestinal microbiota changes in obese girls with polycystic ovary syndrome","volume":"16","author":"Jobira","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2026.114711_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8071054","article-title":"Hydrogen Sulfide as a toxic product in the small-large intestine Axis and its role in IBD development","volume":"8","author":"Kushkevych","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2026.114711_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8101656","article-title":"The Sulfate-reducing microbial communities and meta-analysis of their occurrence during diseases of small-large intestine axis","volume":"8","author":"Kushkevych","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2026.114711_bb0270","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13099-024-00632-w","article-title":"Desulfovibrio vulgaris caused gut inflammation and aggravated DSS-induced colitis in C57BL\/6 mice model","volume":"16","author":"Huang","year":"2024","journal-title":"Gut Pathog."},{"key":"10.1016\/j.jconrel.2026.114711_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/cells12010089","article-title":"Desulfovibrio fairfieldensis-derived outer membrane vesicles damage epithelial barrier and induce inflammation and pyroptosis in macrophages","volume":"12","author":"Nie","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2026.114711_bb0280","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/1462-2920.13589","article-title":"Formation of propionate and butyrate by the human colonic microbiota","volume":"19","author":"Louis","year":"2017","journal-title":"Environ. Microbiol."},{"key":"10.1016\/j.jconrel.2026.114711_bb0285","article-title":"Butyrate producers, \u201cThe sentinel of gut\u201d: their intestinal significance with and beyond butyrate, and prospective use as microbial therapeutics","volume":"13\u20132022","author":"Singh","year":"2023","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jconrel.2026.114711_bb0290","doi-asserted-by":"crossref","DOI":"10.1093\/advances\/nmy125","article-title":"Effects of weight-loss interventions on short-chain fatty acid concentrations in blood and feces of adults: a systematic review","volume":"10","author":"Sowah","year":"2019","journal-title":"Adv. Nutr. (Bethesda, Md.)"},{"key":"10.1016\/j.jconrel.2026.114711_bb0295","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.cmet.2014.05.009","article-title":"IL-6 strikes a balance in metabolic inflammation","volume":"19","author":"Covarrubias","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.jconrel.2026.114711_bb0300","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.17023.1","article-title":"Tumour necrosis factor signalling in health and disease","volume":"8","author":"Holbrook","year":"2019","journal-title":"F1000Res"},{"key":"10.1016\/j.jconrel.2026.114711_bb0305","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2147\/IJN.S486709","article-title":"Permeability-enhancing and protective effect on small intestine of punicic acid in different forms and their nanoemulsions with low toxicity","volume":"20","author":"Duan","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.114711_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2024.110954","article-title":"Brain-derived neurotrophic factor levels across psychiatric disorders: a systemic review and network meta-analysis","volume":"131","author":"Zou","year":"2024","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jconrel.2026.114711_bb0315","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/2823671","article-title":"Antidiabetic effect of brain-derived neurotrophic factor and its association with inflammation in type 2 diabetes mellitus","volume":"2017","author":"Eyileten","year":"2017","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.jconrel.2026.114711_bb0320","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1007\/s12035-015-9461-2","article-title":"Serum levels of brain-derived neurotrophic factor are associated with diabetes risk, complications, and obesity: a cohort study from Chinese patients with type 2 diabetes","volume":"53","author":"Li","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jconrel.2026.114711_bb0325","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/978143","article-title":"Relationship between levels of brain-derived neurotrophic factor and metabolic parameters in patients with type 2 diabetes mellitus","volume":"2014","author":"Boyuk","year":"2014","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.jconrel.2026.114711_bb0330","doi-asserted-by":"crossref","first-page":"12200","DOI":"10.1038\/s41598-017-11744-6","article-title":"Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD","volume":"7","author":"Pierantonelli","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.114711_bb0335","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s11605-021-05188-7","article-title":"The role of gut-derived lipopolysaccharides and the intestinal barrier in fatty liver diseases","volume":"26","author":"An","year":"2022","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.jconrel.2026.114711_bb0340","doi-asserted-by":"crossref","first-page":"6701","DOI":"10.1038\/s41598-023-33806-8","article-title":"Gut microbiota induces hepatic steatosis by modulating the T cells balance in high fructose diet mice","volume":"13","author":"Zhou","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.114711_bb0345","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.1038\/s41598-021-84761-1","article-title":"DSS-induced colitis is associated with adipose tissue dysfunction and disrupted hepatic lipid metabolism leading to hepatosteatosis and dyslipidemia in mice","volume":"11","author":"Kwon","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.114711_bb0350","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22063061","article-title":"Butyrate and the fine-tuning of colonic homeostasis: implication for inflammatory bowel diseases","volume":"22","author":"Gasaly","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.114711_bb0355","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.ajpath.2023.06.007","article-title":"The role of gut microbiome-derived short-chain fatty acid butyrate in hepatobiliary diseases","volume":"193","author":"Pant","year":"2023","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2026.114711_bb0360","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.1067647","article-title":"Protective role of butyrate in obesity and diabetes: new insights","volume":"9","author":"Mayorga-Ramos","year":"2022","journal-title":"Front. Nutr."},{"key":"10.1016\/j.jconrel.2026.114711_bb0365","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.770986","article-title":"Endotoxins and non-alcoholic fatty liver disease","volume":"12","author":"Kessoku","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.jconrel.2026.114711_bb0370","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jcmgh.2023.09.002","article-title":"DNMT3B alleviates liver steatosis induced by chronic low-grade LPS via inhibiting CIDEA expression","volume":"17","author":"Li","year":"2024","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2026.114711_bb0375","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/gutjnl-2016-313099","article-title":"Dietary emulsifiers directly alter human microbiota composition and gene expression ex vivo potentiating intestinal inflammation","volume":"66","author":"Chassaing","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2026.114711_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115720","article-title":"Microbiome-active drug delivery systems (MADDS): leveraging microbial stimuli for controlled drug release","volume":"227","author":"Kamath","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114711_bb0385","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1021\/acsami.5b12688","article-title":"Selective antimicrobial activities and action mechanism of micelles self-assembled by cationic oligomeric surfactants","volume":"8","author":"Zhou","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2026.114711_bb0390","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.fct.2017.05.068","article-title":"Are additive effects of dietary surfactants on intestinal tight junction integrity an overlooked human health risk? \u2013 a mixture study on Caco-2 monolayers","volume":"106","author":"Glynn","year":"2017","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.jconrel.2026.114711_bb0395","article-title":"Role of metabolic endotoxemia in systemic inflammation and potential interventions","volume":"11","author":"Mohammad","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.114711_bb0400","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21114077","article-title":"Reg3\u03b1 and Reg3\u03b2 expressions followed by JAK2\/STAT3 activation play a pivotal role in the acceleration of liver hypertrophy in a rat ALPPS model","volume":"21","author":"Otsuka","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.114711_bb0405","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2393270","article-title":"The interplay between gut microbiota, short-chain fatty acids, and implications for host health and disease","volume":"16","author":"Hays","year":"2024","journal-title":"Gut Microbes"},{"key":"10.1016\/j.jconrel.2026.114711_bb0410","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.bbi.2019.07.003","article-title":"Interplay between inflammation and neural plasticity: both immune activation and suppression impair LTP and BDNF expression","volume":"81","author":"Golia","year":"2019","journal-title":"Brain Behav. Immun."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926001136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926001136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T08:31:04Z","timestamp":1787128264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926001136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":82,"alternative-id":["S0168365926001136"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114711","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114711","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114711"}}